ALNYLAM PHARMACEUTICALS, INC. company info

CIK 1178670
IRS Number 770602661
State of incorporation None
Business address 300 THIRD STREET
None
CAMBRIDGE
MA
02142
Mail address 300 THIRD STREET
None
CAMBRIDGE
MA
02142

Short summary

ALNYLAM PHARMACEUTICALS, INC. is a Massachusetts company, with head office located at 300 Third Street Cambridge, Massachusetts 02142. In 2017 the company owned a total of 1.92 billion USD worth of assets, including 1.69 billion USD worth of current assets. The company amassed the most assets last year, totalling up to 1.92 billion USD.

ALNYLAM PHARMACEUTICALS, INC. Income Statement

Name [in Millions USD]20072008200920102011201220132014201520162017Trends
Revenue, Net 96.16100.53100.04
Research and development 96.88108.73106.3899.3086.57112.96190.25276.50382.39390.64
Operating Expenses 124.00148.64144.11137.58196.18140.11455.54337.11471.75590
Operating Income (Loss) -27.84-48.11-44.07-54.82-129.46-92.94-404.98-296.01-424.59-500.09
Interest expense 0.87
Other Nonoperating Income (Expense) -1.950.636.40-0.530.33-0.051.820.086.17-3.02
Income Tax Expense (Benefit) 0.720.580.510-10.57-2.70-40.210
Net income -26.25-47.59-43.52-57.65-106.01-89.23-360.40-290.07-410.11-490.87

ALNYLAM PHARMACEUTICALS, INC. Balance Sheet

Name [in Millions USD]20072008200920102011201220132014201520162017Trends
Cash and cash equivalents 105.16147.8766.1867.1148.2724.9880.73151.26271.08408.67396.15
Deferred income taxes 1.940
Property, Plant and Equipment, Gross 45.5755.2757.7667.8379.31175.58249.25
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment 30.9235.4741.3246.0951.4961.0167.35
Available-for-sale Securities, Noncurrent 137.7298.0863.74164.82
Other Assets, Noncurrent 0.840.101.471.475.22
Total assets 440.18340.83318.48462.561,032.661,530.771,382.161,434.281,923.14
Current assets 273.51224.33240.34214.36665.121,029.15888.07960.711,685.30
Accounts payable 10.407.955.524.536.1715.7212.8223.1713.21
Total current liabilities 102.03100.5357.0653.0753.7566.6070.58108.73115.38
Deferred Revenue, Noncurrent 169.96100.1268.1197.6432.5550.2654.8142.087.68
Total liabilities 274.70204.28130.19154.3890.39122.17283.68311.32168.33
Common Stock, Value, Issued 0.420.430.520.620.760.850.860.921.01
Retained Earnings (Accumulated Deficit) -326.79-373.46-425.32-534.19-891.25-1,079.19-1,439.81-1,882.52-2,220.69
Accumulated Other Comprehensive Income (Loss), Net of Tax 1.29-0.25-0.0628.1321.9818.76-28.30-33.96-34.85

ALNYLAM PHARMACEUTICALS, INC. Cash Flow

Name [in Millions USD]20072008200920102011201220132014201520162017Trends
Net income -26.25-47.59-43.52-57.65-106.01-89.23-360.40-290.07-410.11-490.87
Depreciation 4.8054.606.1056.709.6011.90
Depreciation and amortization 5.735.994.945.139.0410.2311.9319.0515.1313.37
Accounts payable -1.249.90-3.18-3.51-1.741.838.841.6810.10-4.94
Deferred revenue 66.67-58.17-60.71-70.26-8.56-6.20-7.791.9014.621.85
Net Cash Provided by (Used in) Operating Activities 65.49-72.15-84.34-87.07-115.61-68.66
Payments to Acquire Property, Plant, and Equipment 10.764.954.731.298.354.018.9612.9564.56104.21
Payments to Acquire Intangible Assets 25
Net Cash Provided by (Used in) Investing Activities 17.9414.4317.8481.963.37-130.51
Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3.37-130.51-548.81-321.32142.59-290.36
Proceeds from Issuance of Common Stock 5.411.150.9986.80173.57496.401,139.63
Net Cash Provided by (Used in) Financing Activities 3.163.513.660.7493.41200.93
Cash and Cash Equivalents, Period Increase (Decrease) 86.64-54.32-62.87-4.37-18.821.7622.01105.7212.72451.74